Summary Immunohistochemical antibody techniques for detection of oestrogen receptors (ER) were applied to formalin fixed, paraffin embedded sections from 62 primary breast cancers, the metastases of their original regional lymph nodes (29 cases), bone marrow carcinosis (43 cases) and liver metastases (20 cases). Forty per cent of the primary tumours and 31% of the regional lymph node metastases were ER positive; in contrast, less than 20% of liver and bone marrow metastases were ER positive. The The presence of oestrogen receptors (ERs) is associated with a prolonged survival in patients with both primary and recurrent breast cancer. This probability applies both to an increased effect of endocrine therapy in receptor positive patients (Alanko et al., 1985; Howell et al., 1984; Rose et al., 1985) and to qualitative differences between ER positive and negative tumours (Clark et al., 1987; Parl et al., 1984; Shek et al., 1987) .
Summary Immunohistochemical antibody techniques for detection of oestrogen receptors (ER) were applied to formalin fixed, paraffin embedded sections from 62 primary breast cancers, the metastases of their original regional lymph nodes (29 cases), bone marrow carcinosis (43 cases) and liver metastases (20 cases). Forty per cent of the primary tumours and 31% of the regional lymph node metastases were ER positive; in contrast, less than 20% of liver and bone marrow metastases were ER positive. The ER status of regional lymph node metastases was concordant with that of the primary tumour in 90% of the cases. The concordance rate was 75% for liver metastases and 58% for bone metastases. Patients with ER positive primary tumours had recurrence significantly more often in bone; ER negative tumours recurred more often in the liver. The survival after recurrence (SAR) was significantly related to the ER status of the primary tumour and to that of the regional lymph node metastases. In contrast, the SAR was not associated with the ER status of bone marrow carcinosis or liver metastases. Cox analyses showed that age and ER status of the primary tumour were the most important independent prognostic factors compared to other clinical, therapeutic, pathoanatomical and biochemical features. The study supports the hypothesis that tumour cell clones with different ER content are selected and adapted to grow in various anatomical sites. Moreover, the ER status of the primary tumour seems to be more important for the prognosis than the ER status of bone and liver metastases.
The presence of oestrogen receptors (ERs) is associated with a prolonged survival in patients with both primary and recurrent breast cancer. This probability applies both to an increased effect of endocrine therapy in receptor positive patients (Alanko et al., 1985; Howell et al., 1984; Rose et al., 1985) and to qualitative differences between ER positive and negative tumours (Clark et al., 1987; Parl et al., 1984; Shek et al., 1987) .
The ER status of a given tumour should be regarded as a reflection of the average receptor content from cell clones with varying receptor contents. It is unknown whether clones with different receptor content metastasise to different organs or whether it is the 'average' ER content per se which reflects specific biological subtypes. The purpose of the present study is to describe and to compare the immunohistochemical ER content in primary breast cancer, involved regional lymph nodes and subsequent distant metastases. Moreover, prognostic importance of site-specific differences has been investigated.
Materials and methods
The patients all participated in a prospective investigation programme for patients with recurrent breast cancer. The organisation and results of this study have been published previously (Kamby et al., 1987b obtain tissue for histological verification of metastasis (Kamby et al., 1987a) .
All metastatic sites detected within 1 month after the diagnosis of the first site of metastasis were grouped together and designated as the sites of first recurrence. The sites of metastases were recorded according to anatomical location. When the number of sites was calculated, the presence of recurrence in each anatomical location counted for one, irrespective of the number of tumour deposits within each site.
Among the 394 evaluable patients who entered the investigation programme, 111 patients had histologically verified liver metastases and/or bone marrow carcinosis. Of these, paraffin embedded specimens from the primary tumour were available from 76 patients. In 14 cases, either the primary tumour specimen (eight patients) or the metastatic tissue (six patients) was not evaluable by the immunohistochemical method. This leaves 62 patients with immunohistochemical ER determination of both the primary tumour and a metastasis. Twenty-nine of the patients had locoregional metastases at the time of primary diagnosis. The ER status of these metastases was also determined.
The ER analyses were made on sections from formalin fixed and paraffin embedded tissue blocks from the primary tumour, the concomitant regional lymph node metastases, the sure-cut liver biopsies and the positive bone marrow aspiration clots. The metastatic samples were obtained a median of 27 months (25-75%: 11-50 months) after initial presentation.
The method for the immunohistochemical detection of ER has beeen described in detail elsewhere (Rasmussen & Kamby, 1989) . Briefly, after dehydration in xylol and decreasing concentrations of alcohol, the sections were incubated with trypsin, 0.1%, for 2h. After being rinsed in PBS, the sections were incubated with 5% human serum in order to reduce background staining. The incubation with primary antibody, 10#gml-' in 5% human serum, took place overnight at 40°C. The antibody was a special supply from G. Greene, Ben Mai Institute, University of Chicago. It is known to react reasonably well on paraffin embedded material (De Rosa et al., 1987) . After repeated rinsing, the sections were incubated with peroxidase-conjugated goatantirat, 1:50 in 5% human serum, for 30min. A positive reaction was visualised with diamino-benzidine (DAB). A (Andersen et al., 1981) .
Treatment of recurrent disease
Premenopausal patients were castrated with irradiation and received combination chemotherapy. Post-menopausal patients below the age of 65 years received tamoxifen and three-drug combination chemotherapy. Patients above 65 years of age received endocrine therapy only.
Statistical methods
For comparison of qualitative data, the X2 test and the Mann-Whitney rank sum test for unpaired samples were used (Bross, 1954) . Survival data were calculated from the time of first recurrence (i.e. survival after recurrence, SAR). Univariate survival distributions were estimated using the Kaplan-Meier product limit procedure, and the log.rank test was used to evaluate the differences in survival rates (Peto et al., 1977) . The Cox proportional hazards model (Cox, 1972) was used to test the influence of univariate significant features on the effect of ER status on SAR. A P value of less than 0.05 was considered significant.
Results

Patient characteristics
The mean age at the time of recurrence was 53 years (range 30-74 years). Of the primary tumours, 58% were >3cm, and two-thirds of the patients had positive axillary nodes.
Seventy per cent received systemic adjuvant therapy; adjuvant endocrine therapy with or without chemotherapy was given to 24% of the patients. Within two years 40% of the patients had recurrence. The mediation duration of the recurrence-free interval was 27 months (25-75% fractiles 11-50 months). Table I shows that both pathoanatomical and demographic as well as clinical characteristics were unassociated with the ER content of the primary tumour.
Oestrogen receptor data Immunohistochemical examination of tumour tissue from both the primary tumour and a metastasis was possible in 62 patients (43 of these had bone marrow carcinosis; 20 patients had liver metastases; one patient had both bone and liver lesions). The ER content of metastases from regional lymph nodes was determined in 29 of the patients.
Sixty per cent of the primary tumours did not contain ER (i.e. they were ER negative). The prevalence of ER negativity increased with increasing metastatic spread. Thus, 82% and 95% of the bone and liver metastases were ER negative compared to 69% of the regional lymph node metastases. In contrast, less than 10% of the liver and bone marrow metastases were ER rich, while 30% of the primary tumours had a high ER content (Table II) . The ER status of metastases in regional lymph nodes was concordant (+ / + or -/ -) with the ER status of the primary tumours in 90% of the patients. The concordance rates for primary tumour versus bone marrow and versus liver metastases were 58% and 75%, respectively (Table III) . Table III also shows that the discordance rate (ER positive primary tumour/ER negative metastasis) was higher for metastases in bone and liver compared to metastases in regional lymph nodes. (Figure 2) . Forty-six patients had radiological bone metastases, and 23 patients had more than two bone regions involved. The extent (number) of radiographic bone lesions was similar in ER positive and negative patients (P=0.14). The predominant radiographic morphology was osteolysis (77%) followed by mixed (26%) and osteosclerotic (12%) lesions. The radiological appearance of bone metastases was unassociated with the ER content.
Survival data
The median period of observation after first recurrence was 39 months (range 26-55 months); at the time of follow-up (May 1988), 51 patients (82%) had died. The median survival after recurrence (SAR) was 10 months (25-75% fractiles 3-26 months).
Univariate survival analyses of clinical and pathoanatomical characteristics showed that increasing age, decreased serum albumin and increasing number of metastases were features of a short SAR. The SAR was not significantly associated with differences in laterality and location of the primary tumour, tumour size, regional lymph node status, number of positive nodes, recurrence-free interval, adjuvant therapy, number of bone metastases and treatment of recurrent disease (Table IV) .
The SAR was significantly related to the ER status of both the primary tumour (P=0.01) and the regional lymph node metastases (P=0.004) (Figure 3 ). In contrast, the SAR was not associated with the ER status of bone marrow carcinosis and liver metastases (Table V) . In order to identify patients with extremely poor prognosis, patients with concordant ER negative tissues from both the primary tumour and a metastasis were grouped together. The SAR of these patients was compared with the survival of paients with discordant or concordant ER positive tumours. Patients with concordant ER negative primary tumours/regional nodes, primary tumours/bone marrow or regional nodes/ bone marrow all had a significantly shorter survival than the SAR of patients with other receptor profiles (Figure 4) . However, patients with liver metastases all had a very short survival, irrespective of both the ER profile (Table V and Figure 4 ). (5-27) (3-28) (3-19) (6-28) (2-19) (5-24) (3-25) (7-28) (4-24) (2-24) (4-25) (2-44) (3-24) (4-27) (3-26) (7-13) (3-28) 13 (5-25) 9 (2-24) The development of techniques for immunohistochemical studies of paraffin sections has made it possible to apply this method to greater retrospective series of biopsies (Andersen et al., 1986) . Thus, the present study was performed retrospectively on biopsies from a prospective, consecutive group of patients who entered a protocolled investigation programme for recurrent breast cancer.
Multivariate regression analyses
The study shows that use of the immunohistochemical method on paraffin embedded sections is possible. Moreover, the immunohistochemical method has the advantage over the biochemical method that it is possible to assess the tumour heterogeneity. The results of the method have an acceptable agreement with the biochemical method. Thus, we found an overall concordance rate of 93% with the biochemical method (Rasmussen & Kamby, 1989) .
The relatively high proportion of ER negative primary tumours (60%) may be due to the fact that all our patients had distant recurrences. Thus, ER positive patients (with a good prognosis) are more often without recurrence. Our patients were not only selected among patients with recurrence, but also among a subgroup of patients with a particularly poor prognosis (i.e. distant metastases). Moreover, a proportion of the ERs may be destroyed during Theoretically, the ER status may influence survivavl by (1) variations in the growth rate, (2) variations in the degree of spread, or (3) differences in the anatomical location of the metastases. ER negative tumours have a high labelling index (Silvestrini, 1981) and a faster rate of progression (Kamby et al., 1988) . This indicates that the poor prognosis for ER negative patients is due to a relatively high rate of growth (Adami et al., 1985) . The present study shows that the poor prognosis for ER negative patients is probably not mediated through a propensity to develop multiple metastases. Thus, the number of metastatic sites was similar in ER positive and negative patients. ER positive tumours had a propensity to metastasise to bone, while ER negative tumours often recurred in viscera. This pattern is in accordance with the main part of the literature (Clark et al., 1987; Kamby et al., 1988) . This distribution is in agreement with the hypothesis that the ER status also influences prognosis because of ERrelated variations in the pattern of spread.
In conclusion, the study shows that immunohistochemical ER status of the primary tumour evaluated on paraffin sections has independent prognostic importance for the Analyses are based on a complete data set from 29 patients, of whom 24 (93%) have died.
duration of post-recurrent survival in breast cancer. The receptor contents of the primary tumour and of the metastases were usually concordant, although there was a tendency for lower receptor content in the metastases. The high rate of concordance is related to the relatively high prevalence of ER negative primary tumours (60%). Thus, a shift from a negative primary tumour to positive metastases was seen in only two patients with bone marrow carcinosis, and in no patients with liver metastases. The reverse disconcordance rate (positive to negative) was 73% and 83% for patients with bone and liver metastases, respectively. This suggests that the decision on endocrine therapy should be based on the ER status of the metastases.
